← Leaderboards
Jianlong Wang
Icahn School Of Medicine At Mount Sinai
$10,059,386
Attributed
$11,497,444
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,497,444 · 10
By mechanism
R01$10,578,944 · 8
R21$918,500 · 2
Top collaborators
- Mingjiang Xu7 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Prashanth Rangan$5,407,868
- James J Bieker$21,475,352
- Daifeng Wang$4,934,175
- Ernesto Guccione$11,143,318
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsEmbryonic Stem CellPluripotencyCellsGenesGenetic TranscriptionMolecularStem CellsPlayPluripotent Stem CellsMalignant NeoplasmsKnock-OutEpigenetic ProcessIn VivoGene Expression RegulationMediatingProteomicsBindingChromatinTranscriptomeInsightCoupledReportingEmbryo
Grant awards (35)
Therapeutic value and mechanistic action of PSPC1 in AML$600,374
R01 · FY2025 · CA
A Nucleolar Paradigm for Pluripotency of Human Embryonic Stem Cells$540,272
R01 · FY2025 · HD · contact PI
Transcriptional and Epigenetic Control of Totipotency and Early Development by Zfp281$339,808
R01 · FY2025 · HD · contact PI
Decoding NSUN2-mediated translational control of pluripotent stem cells$246,750
R21 · FY2025 · HD · contact PI
Therapeutic value and mechanistic action of PSPC1 in AML$614,749
R01 · FY2024 · CA
A Nucleolar Paradigm for Pluripotency of Human Embryonic Stem Cells$540,272
R01 · FY2024 · HD · contact PI
Decoding NSUN2-mediated translational control of pluripotent stem cells$205,625
R21 · FY2024 · HD · contact PI
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$413,948
R01 · FY2022 · HL
Defining Novel Molecular Pathways to Totipotency$329,428
R01 · FY2022 · HD · contact PI
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells$329,427
R01 · FY2022 · HD · contact PI
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$413,488
R01 · FY2021 · HL
Defining Novel Molecular Pathways to Totipotency$329,428
R01 · FY2021 · HD · contact PI
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells$329,427
R01 · FY2021 · HD · contact PI
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281$324,000
R01 · FY2021 · GM · contact PI
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$412,845
R01 · FY2020 · HL
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control in pluripotent stem cells$336,150
R01 · FY2020 · HD · contact PI
Defining Novel Molecular Pathways to Totipotency$336,150
R01 · FY2020 · HD · contact PI
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281$324,000
R01 · FY2020 · GM · contact PI
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control$351,713
R01 · FY2019 · HD · contact PI
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$340,628
R01 · FY2019 · HL
Defining Novel Molecular Pathways to Totipotency$264,071
R01 · FY2019 · HD · contact PI
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281$168,780
R01 · FY2019 · GM · contact PI
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281$162,689
R01 · FY2019 · GM · contact PI
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$80,084
R01 · FY2019 · HL
Defining Molecular Pathways to Expanded Puripotentiality$75,416
R01 · FY2019 · HD · contact PI
Defining Molecular Pathways to Expanded Puripotentiality$351,713
R01 · FY2018 · HD · contact PI
RNA-dependent chromatin targeting of TET2 for endogenous retrovirus control$349,982
R01 · FY2018 · HD · contact PI
Transcriptional and Epigenetic Control of Pluripotency and Development by Zfp281$339,000
R01 · FY2018 · GM · contact PI
Catalytic Activity Independent Functions of TET Proteins in Pluripotency$254,250
R21 · FY2017 · HD · contact PI
Catalytic Activity Independent Functions of TET Proteins in Pluripotency$211,875
R21 · FY2016 · HD · contact PI
Oct4 and epigenetic regulation of stem cell pluripotency$318,660
R01 · FY2015 · GM · contact PI
Oct4 and epigenetic regulation of stem cell pluripotency$318,660
R01 · FY2014 · GM · contact PI
Oct4 and epigenetic regulation of stem cell pluripotency$307,507
R01 · FY2013 · GM · contact PI
Oct4 and epigenetic regulation of stem cell pluripotency$318,660
R01 · FY2012 · GM · contact PI
Oct4 and epigenetic regulation of stem cell pluripotency$317,615
R01 · FY2011 · GM · contact PI